Early impact of nirsevimab on ambulatory all-cause bronchiolitis: a prospective multicentric surveillance study in France.

Corinne LevyAndreas WernerAlexis RybakStéphane BéchetChristophe BatardFrédéric HassidRoxane DesandesBruno FrandjiNaim OuldaliRobert Cohen

Published in: Journal of the Pediatric Infectious Diseases Society (2024)

After implementation of nirsevimab in 2023 in France as compared with 2022-2023, we found a 52.7%, 95% CI [46.4-58.9]) decrease in all-cause bronchiolitis in children <3 months with the lowest number of bronchiolitis cases in this population since 2017.

Keyphrases

respiratory syncytial virus
healthcare
primary care
young adults
quality improvement